B+
Bull case
30%
Probability
Target price
$24.00
+71.9% vs current
AVTX
Avalo TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$15.00
+7.4% vs current
B-
Bear case
30%
Probability
Target price
$8.00
-42.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+60.7
Score
AI commentary
This remains a cautious monitoring setup rather than a high-conviction bullish thesis. Primary sources now clearly support the two key positives: Q2 2026 LOTUS timing and runway into 2028 [#10-K-2026-03-23]. But the deterministic prior is still near-neutral/slightly negative, catalyst density is only moderate, and almost all upside depends on a single readout. Recent conference/news flow points to investor focus on the same AVTX-009 Phase 2 window [#SERP-2][#SERP-3], which reinforces that the stock is likely to trade as a binary event vehicle until data.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventRunway confirmation reduces near-term dilution pressure ahead of dataHigh impact
The 10-K reported $98.3 million of cash, cash equivalents and short-term investments at December 31, 2025 and said current resources are expected to fund operations into 2028, which should keep near-term financing pressure lower as AVTX approaches LOTUS data [#10-K-2026-03-23].
2026-06-30catalystPhase 2 LOTUS topline data in Q2 2026High impact
Avalo’s 10-K says abdakibart (AVTX-009) is the lead asset, LOTUS enrollment was completed in October 2025, and management is preparing for a topline readout in the second quarter of 2026; this is the main value-setting catalyst for the stock [#10-K-2026-03-23].
2026-09-30eventPost-readout Phase 3 decision could surface milestone and capital implicationsHigh impact
Avalo said it is planning for Phase 3 trial(s), and the 10-K also notes a $15 million AlmataBio development milestone becomes due upon first patient dosed in a Phase 3 trial, payable in cash or stock at the holders’ election; a positive LOTUS outcome could therefore quickly shift debate to pivotal-trial design and funding terms [#10-K-2026-03-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology